Effects of Azithromycin on Airway Oxidative Stress Markers in Patients With Bronchiectasis

• Status: Completed
• Trial end date: 2007-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The mechanism by which macrolide antibiotics have immune modifying effects independent from its antibacterial activity has not been well established. In the present work, the investigators will analyze the effect of long-term treatment with azithromycin (250 mg three times per week during three months) on airway oxidative stress markers in exhaled breath condensate of adult patients with stable non-CF bronchiectasis.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Instituto de Investigacion Sanitaria La Fe
• Collaborator: Sociedad Valenciana de Neumología
• Treatments: Azithromycin

Criteria

Inclusion Criteria:

• Previous diagnosis of bronchiectasis based on lung HRCT and clinical symptoms

• Clinically stable in previous four weeks without exacerbations

• Informed consent

Exclusion Criteria:

• Bronchiectasis secondary to Cystic fibrosis, pulmonary surgical processes, immune deficiency, emphysema, allergic bronchopulmonary aspergillosis or diffuse interstitial pulmonary diseases

• Intolerance to macrolides or severe liver disease.